Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AbSci, Sanofi Enter Mfg. Platform Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

AbSci, Sanofi Enter Mfg. Platform Pact

AbSci will apply its SoluPro manufacturing platform and optimization assay to two of Sanofi's biotherapeutic molecules

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbSci, a biotherapeutic discovery and manufacturing technologies company, has entered a collaboration with Sanofi. AbSci will apply its E.coli manufacturing platform, SoluPro, and its optimization assay system, to two of Sanofi’s biotherapeutic molecules. AbSci’s technology platform is designed with the ability to rapidly achieve optimized, scalable, high-quality, high-titer production of any class of biotherapeutic molecule, including traditionally difficult to manufacture molecules and next-generation scaffolds. The collaboration will take place at AbSci and will be funded by Sanofi.

“It is exciting to partner with a renowned company like Sanofi,” said Sean McClain, chief executive officer of AbSci. “This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We’ve shown SoluPro can uniquely deliver on this industry need.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics